BRIN.TA - Brainsway Ltd.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
2,063.00
-3.00 (-0.15%)
At close: 2:24PM IDT
Stock chart is not supported by your current browser
Previous Close2,066.00
Open2,021.00
Bid2,062.00 x 19800
Ask2,063.00 x 24100
Day's Range2,021.00 - 2,077.00
52 Week Range1,550.00 - 2,750.00
Volume57,753
Avg. Volume53,114
Market Cap446.441M
Beta (3Y Monthly)0.59
PE Ratio (TTM)N/A
EPS (TTM)-0.39
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire4 hours ago

    Brainsway Ltd. Announces Closing of Initial Public Offering

    Brainsway Ltd. (NASDAQ: BWAY and TASE: BRIN) (“Brainsway”) today announced that it has closed its initial public offering of 2,500,000 American Depositary Shares (“ADSs”), each representing two ordinary shares of Brainsway, at a public offering price of $11.00 per ADS. The gross proceeds to Brainsway from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, are approximately $27.5 million. The underwriters have been granted an option to purchase up to an additional 375,000 ADSs offered by Brainsway for a period of 30 days after the pricing date.

  • GlobeNewswire6 days ago

    Brainsway Ltd. Announces Pricing of Initial Public Offering of 2.5 Million American Depositary Shares

    Brainsway Ltd. (NASDAQ: BWAY and TASE: BRIN) (“Brainsway”) today announced that it has priced its initial public offering of 2,500,000 American Depositary Shares (“ADSs”), each representing two ordinary shares of Brainsway, at a public offering price of $11.00 per ADS. The gross proceeds to Brainsway from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $27.5 million.

  • GlobeNewswire19 days ago

    Join Achieve TMS East to Celebrate the Grand Opening of its Woburn Location

    Achieve TMS East, Massachusetts’ largest provider of Deep Transcranial Magnetic Stimulation (Deep TMS) therapy for the treatment of depression and Obsessive-Compulsive Disorder (OCD), is pleased to announce the opening of its newest center in Woburn, Mass. Achieve TMS East will be celebrating the opening of its Woburn office with a Ribbon Cutting Ceremony and Open House on Thursday, April 11, from 12:00 – 1:30 p.m. at 400 West Cummings Park, Suite 4175, Woburn, MA.  Among the distinguished guests will be Achieve TMS East psychiatrist, Dr. Sangeeta Banerjee, and Marjorie Pierce, Director of Operations for Achieve TMS East. The Ribbon Cutting ceremony will begin promptly at 12:00 p.m. and guests will then have the opportunity to tour the facility, participate in an informative presentation with a Q&A and witness a hands-on demo with the TMS machine.

  • GlobeNewswire25 days ago

    Ventre Medical Associates Hosts Quarterly Meet and Greets to Offer Tour of its Deep TMS and Depression Clinic

    Ventre Medical Associates, a full-service psychiatric clinic offering expert consultation, evaluation and treatment of mental health disorders, announced that it will be hosting quarterly meet and greets, in which local clinicians will have the opportunity to tour its Deep TMS and depression clinic. The open house events will feature the advanced treatment of BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS), a non-invasive, non-medication treatment that is FDA-cleared for the treatment of depression. Eric Tirado, Ventre Medical patient, said, "I have battled with depression for over 20 years, having undergone various hardships, including discovering that I was HIV positive, had a serious medical condition that required surgery, and losing my partner of almost two decades to a massive heart attack.

  • GlobeNewswire26 days ago

    Brainsway Reports Financial Results for Fourth Quarter and Full-Year 2018

    Full-Year 2018 revenues of $16.4 million increased 47% over full-year 2017 Fourth quarter revenues of $4.8 million, up 32% over the prior year quarter HACKENSACK, N.J., March.

  • GlobeNewswirelast month

    Join Achieve TMS East to Celebrate the Grand Opening of its Andover Location

    Achieve TMS East, Massachusetts’ largest provider of Deep Transcranial Magnetic Stimulation (Deep TMS) therapy for the treatment of depression and obsessive-compulsive disorder (OCD), is pleased to announce the opening of its newest center in Andover, Massachusetts. Achieve TMS East will be celebrating the opening of its Andover office with a ribbon cutting ceremony and open house on Friday, March 22, from 12:00 to 1:30 p.m. at 2 Dundee Park Dr., Andover, Massachusetts.  Among the distinguished guests will be State Senator, Barry Finegold and Director of Operations for Achieve TMS East, Marjorie Pierce.

  • GlobeNewswire2 months ago

    BrainsWay Announces New Clinical Support Program for Physicians Treating Obsessive-Compulsive Disorder: – “BrainsWay OCD Launchpad to Success”

    BrainsWay Ltd. (TASE:BRIN), the parent company of BrainsWay USA, Inc., and a global leader in the advanced non-invasive treatment of brain disorders, today announced the initiation of “Launchpad to Success,” a program to support physicians as they introduce patients to the company’s deep transcranial magnetic stimulation (dTMS) system for the treatment of Obsessive-Compulsive Disorder (OCD) in adults. BrainsWay’s Deep TMS technology received De Novo clearance from the U.S. Food and Drug Administration (FDA) for the treatment of OCD in adults in August 2018.

  • GlobeNewswire2 months ago

    BrainsWay Expands Intellectual Property Position by Obtaining Rights to Multi-Channel Transcranial Magnetic Stimulation Patent Portfolio

    BrainsWay Ltd. (TASE:BRIN), a global leader in the advanced non-invasive treatment of brain disorders, today announced that it has acquired an extensive multi-channel transcranial magnetic stimulation (TMS) patent portfolio from TMS Innovations (formerly Rio Grande Neurosciences, Inc.), and has additionally entered into an exclusive option agreement with Stanford University which grants BrainsWay the option to exclusively in-license additional multi-channel TMS-related patents. BrainsWay’s Deep TMS system has been FDA cleared for the treatment of major depressive disorder since 2013, and recently received FDA clearance (De Novo) for the treatment of Obsessive Compulsive Disorder (OCD).  BrainsWay is currently developing a next-generation multi-channel TMS stimulator that has the potential to enable modulation for different areas of the brain with independent stimulation parameters, either simultaneously or sequentially, with high-resolution control for pulse timing.

  • GlobeNewswire2 months ago

    Silicon Valley TMS Now Offering Cutting Edge Mental Health Technology for Obsessive-Compulsive Disorder (OCD) in Northern California

    Silicon Valley TMS, an integrated, multidisciplinary private practice group providing a full range of outpatient mental health and chemical dependency services, today announced that it will be one of the first practices in Northern California to offer its patients access to BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) therapy for Obsessive-Compulsive Disorder (OCD). Silicon Valley TMS currently utilizes Deep TMS for patients living with depression in its San Jose, Pleasanton, Santa Cruz, San Francisco and Mountain View practices. “Treating patients in one of the most populated states in the country, California physicians are grappling with meeting the needs of many individuals with mental illness in the state who do not receive necessary treatment,” said Saad A. Shakir, M.D., chief medical officer at Silicon Valley TMS.

  • GlobeNewswire2 months ago

    BrainsWay Expands its Deep TMS Commercial Footprint into Asia Pacific

    BrainsWay Ltd. (BRIN.TA), a global leader in the advanced non-invasive treatment of brain disorders, today announced that the Company has entered an exclusive distribution agreement with With Healthcare, a leading distributor of medical devices, to market BrainsWay’s Deep Transcranial Magnetic Stimulation System (Deep TMS) in South Korea.  With Healthcare will be responsible for all sales, marketing and commercial activities related to Deep TMS in South Korea.

  • GlobeNewswire2 months ago

    Calabasas Behavioral Health and BrainsWay Host “After the Smoke Clears”

    Calabasas Behavioral Health, a leading mental health service provider in Southern California, announced today that it is partnering with BrainsWay, the global leader in the advanced non-invasive treatment of brain disorders, to offer free mental health programs at its joint benefit, After the Smoke Clears, which will take place on Sunday, February 17 at 23622 Calabasas Road, Suite 320, Calabasas, California. In light of the Woolsey Fire and Borderline Bar and Grill mass shooting, the two organizations will be educating the public on coping mechanisms to help people in Calabasas and the neighboring communities recover from the recent tragedies.

  • GlobeNewswire3 months ago

    BrainsWay Receives PMDA Approval in Japan of Deep Transcranial Magnetic Stimulation System for Treatment of Major Depressive Disorder

    BrainsWay Ltd. (BRIN.TA), a global leader in the advanced non-invasive treatment of brain disorders, today announced that its Deep TMS System has been approved in Japan by the Pharmaceuticals and Medical Devices Agency (PMDA) for the treatment of patients suffering from Major Depressive Disorder (MDD) who did not benefit from previous antidepressants. The PMDA approval was obtained in collaboration with BrainsWay’s exclusive distributor in Japan, Century Medical, Inc. (CMI), an ITOCHU Group company.

  • GlobeNewswire3 months ago

    Brooklyn Minds Now Treats Obsessive-Compulsive Disorder Patients with Transcranial Magnetic Stimulation (Deep TMS)

    Brooklyn Minds, a concierge mental health facility providing comprehensive and highly collaborative child, adolescent and adult mental health services, announced today that patients can now receive BrainsWay’s Deep Transcranial Magnetic Stimulation therapy for Obsessive-Compulsive Disorder (OCD). “In New York State, the prevalence of adults coping with a severe mental illness during 2014 was 598,000 adults, or about 3.9 percent of the population,” said Owen Muir, M.D., Medical Director at Brooklyn Minds.

  • GlobeNewswire4 months ago

    BrainsWay Selected to Participate in FDA Innovation Challenge: Devices to Prevent and Treat Opioid Use Disorder

    BrainsWay Ltd. (BRIN.TA), the parent company of BrainsWay USA, Inc., and a global leader in the advanced non-invasive treatment of brain disorders, today announces that the Company’s deep transcranial magnetic stimulation (Deep TMS) system was one of only eight medical devices selected by the U.S. Food and Drug Administration (FDA) from over 250 applications to participate in the “FDA Innovation Challenge: Devices to Prevent and Treat Opioid Use Disorder,” a new program launched by the FDA to help combat the opioid crisis.

  • GlobeNewswire5 months ago

    Elements Behavioral Health Announces Adoption of Deep Transcranial Magnetic Stimulation (Deep TMS) for Depression in Tennessee Facility

    Elements Behavioral Health, the owner of behavioral health programs located throughout the United States, announced today that together with HPR Treatment Centers, it is offering BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) for the treatment of depression. The company is first introducing Deep TMS to its facility in Nunnelly, Tennessee, The Ranch℠, which will be the first of three locations to receive the device. “Since our founding, we have been committed to providing the highest quality of care for addiction and mental health illnesses,” says Kirk Kureska, Chief Executive Officer at Elements Behavioral Health.

  • GlobeNewswire5 months ago

    TMS Associates of Pennsylvania First Facility in the State to Treat Obsessive-Compulsive Disorder (OCD) with Deep Transcranial Magnetic Stimulation (Deep TMS)

    TMS Associates of Pennsylvania LLC, Haverford’s leading mental health provider specializing in mood disorders, announced today that it is now offering BrainsWay’s latest FDA-cleared Deep Transcranial Magnetic Stimulation (Deep TMS) therapy to patients with Obsessive-Compulsive Disorder (OCD). The facility has been offering Deep TMS therapy for the treatment of depression since 2016. As the first medical device to be FDA cleared for OCD, Deep TMS can be effective for the many patients in need of relief.

  • GlobeNewswire5 months ago

    Brainsway Reports Financial Results for Third Quarter of 2018 and Provides Corporate Update

    Brainsway Ltd. (BRIN.TA), a leader in the advanced non-invasive treatment of brain disorders, today announced the Company’s financial results for the three months ended September 30, 2018, and provided a corporate update.